Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Izadi R, Arkan E, Jalalvand AR, Akbari V
The lack of extensive longitudinal studies creates hesitation among some healthcare providers and regulatory bodies
After stopping the medication, participants taking semaglutide regained 11.6% of their body weight, and those taking a placebo regained 1.9%, leading to a net weight loss of 5.6% in the semaglutide group and 0.1% in the placebo group
10.1007/s10545-012-9488-8 19
Giannakopoulou O, et al
Known side effects (class effects similar to other GLP-1 medications) Gastrointestinal issues (very common): Nausea: 38-43% of participants vs 11% placebo Diarrhea: 33-35% vs 13% placebo Vomiting: 20-21% vs 0% placebo Constipation: 22-25% vs 9% placebo Decreased appetite: 18-19% vs 9% placebo These are expected with incretin-based therapies and typically improve over time as your body adjusts
